Daunorubicin/cytarabine

Liposomal daunorubicin/Cytarabine is a fixed-dose combination of liposomal bound cytarabine and daunorubicin that delivers the two medications in a 5:1 molar ratio.

Daunorubicin/cytarabine
Cytarabine
daunorubicin
Combination of
CytarabineAntimetabolite
daunorubicinAnthracycline
Clinical data
Trade namesVyxeos
AHFS/Drugs.comMonograph
License data
Pregnancy
category
  • US: B (No risk in non-human studies)
    Routes of
    administration    		by intravenous administration
    Legal status
    Legal status

    It is used in the treatment of acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).[1][2]

    References
    1. "Vyxeos (cytarabine/daunorubicin liposomal) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 2019-03-19.
    2. "Vyxeos (cytarabine and daunorubicin) FDA Approval History". Drugs.com. Retrieved 2018-12-30.
    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.